title: Radioimmunotherapy for hematopoietic cell transplantation.
abstract: Radioimmunotherapy (RIT) represents an attractive strategy to deliver radiation selectively to tumor and other target organs while minimizing toxicity to normal tissues. RIT with β-particle-emitting isotopes targeting CD33, CD45 and CD66 can potentially allow intensification of conditioning before hematopoietic cell transplantation (HCT) in leukemia. Similarly, RIT directed against CD20 has shown promise in the setting of autologous and allogeneic HCT for B-cell lymphomas. α-particle immunotherapy with isotopes such as bismuth-213, actinium-225 and astatinine-211 offers the possibility of more selective and efficient killing of target cells while sparing the surrounding normal cells. Pretargeting strategies may further improve target:normal organ dose ratios. While RIT has demonstrated significant antitumor activity, ultimately, randomized studies will be required to determine if conditioning regimens that include this therapeutic modality can improve patient outcomes after HCT.
authors.affiliation: Columbia University Medical Center, 177 Fort Washington Avenue, 6-435, New York, NY 10032, USA. jgj2110@columbia.edu
authors.forename: Joseph G
authors.initials: JG
authors.lastname: Jurcic
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000532:radiotherapy / Q000628:therapy*; D008223:Lymphoma / Q000532:radiotherapy / Q000628:therapy*; D016499:Radioimmunotherapy; D063268:Sialic Acid Binding Ig-like Lectin 3 / Q000276:immunology; D019172:Transplantation Conditioning
chemical_list: D000911:Antibodies, Monoclonal; D063268:Sialic Acid Binding Ig-like Lectin 3